DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus

GV-TH-01, a Phase 1 open-label trial of a DNA prime—Modified Vaccinia Ankara (MVA) boost vaccine (GOVX-B11), was undertaken in HIV infected participants on antiretroviral treatment (ART) to evaluate safety and vaccine-elicited T cell responses, and explore the ability of elicited CD8+ T cells to con...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Melanie, Heath, Sonya L., Sweeton, Bentley, Williams, Kathy, Cunningham, Pamela, Keele, Brandon F., Sen, Sharon, Palmer, Brent E., Chomont, Nicolas, Xu, Yongxian, Basu, Rahul, Hellerstein, Michael S., Kwa, Suefen, Robinson, Harriet L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053438/
https://www.ncbi.nlm.nih.gov/pubmed/27711228
http://dx.doi.org/10.1371/journal.pone.0163164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053438/
https://www.ncbi.nlm.nih.gov/pubmed/27711228
http://dx.doi.org/10.1371/journal.pone.0163164

Ejemplares similares